MedTrace Logo

Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults

NCT00051454 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2007-08-27

No results posted yet for this study

Summary

This study will examine the safety and immune response to a two-part HIV vaccine. Healthy volunteers who are at low risk of HIV infection will receive either active vaccine or a placebo.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

HIV DNA plasmid vaccine plus recombinant fowlpox vector

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • David A Cooper, MD, DSc · National Centre in HIV Epidemiology and Clinical Research, University of New South Wales

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-03-31
Completion
2005-02-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00051454 on ClinicalTrials.gov